RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기
      • 무료
      • 기관 내 무료
      • 유료
      • SCOPUSKCI등재

        Scanning Nonlinear Dielectric Microscopy : Overview -A High Resolution Tool for Observing Ferroelectric Domains and Nano-domain Engineering-

        Cho, Yasuo The Korean Ceramic Society 2003 한국세라믹학회지 Vol.40 No.11

        A sub-nanometer resolution Scanning Nonlinear Dielectric Microscope (SNDM) was developed for observing ferroelectric polarization. We also demonstrate that the resolution of SNDM is higher than that of a conventional piezo-response imaging. Secondly, we report new SNDM technique detecting higher nonlinear dielectric constants $\varepsilon$$\_$3333/ and $\varepsilon$$\_$33333/. Higher order nonlinear dielectric imaging provides higher lateral and depth resolution. Finally, the formation of artificial small inverted domain is reported to demonstrate that SNDM system is very useful as a nano-domain engineering tool. The nano-size domain dots were successfully formed in LiTaO$_3$ single crystal. This means that we can obtain a very high density ferroelectric data storage with the density above 1T-bits/inch$^2$.

      • SCIESCOPUS

        Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

        Kato, Ken,Cho, Byoung Chul,Takahashi, Masanobu,Okada, Morihito,Lin, Chen-Yuan,Chin, Keisho,Kadowaki, Shigenori,Ahn, Myung-Ju,Hamamoto, Yasuo,Doki, Yuichiro,Yen, Chueh-Chuan,Kubota, Yutaro,Kim, Sung-Ba ELSEVIER 2019 LANCET ONCOLOGY Vol.20 No.11

        <P><B>Summary</B></P> <P><B>Background</B></P> <P>Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients with previously treated advanced oesophageal squamous cell carcinoma.</P> <P><B>Methods</B></P> <P>We did a multicentre, randomised, open-label, phase 3 trial (ATTRACTION-3) at 90 hospitals and cancer centres in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. We enrolled patients aged 20 years and older with unresectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1 expression), at least one measurable or non-measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, a baseline Eastern Cooperative Oncology Group performance status of 0–1, and who were refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy and had a life expectancy of at least 3 months. Patients were randomly assigned (1:1) to either nivolumab (240 mg for 30 min every 2 weeks) or investigator's choice of chemotherapy (paclitaxel 100 mg/m<SUP>2</SUP> for at least 60 min once per week for 6 weeks then 1 week off; or docetaxel 75 mg/m<SUP>2</SUP> for at least 60 min every 3 weeks), all given intravenously. Treatment continued until disease progression assessed by the investigator per RECIST version 1.1 or unacceptable toxicity. Randomisation was done using an interactive web response system with a block size of four and stratified according to geographical region (Japan <I>vs</I> rest of the world), number of organs with metastases, and PD-L1 expression. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival, defined as the time from randomisation until death from any cause, in the intention-to-treat population that included all randomly assigned patients. Safety was assessed in all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT02569242, and follow-up for long-term outcomes is ongoing.</P> <P><B>Findings</B></P> <P>Between Jan 7, 2016, and May 25, 2017, we assigned 419 patients to treatment: 210 to nivolumab and 209 to chemotherapy. At the time of data cutoff on Nov 12, 2018, median follow-up for overall survival was 10·5 months (IQR 4·5–19·0) in the nivolumab group and 8·0 months (4·6–15·2) in the chemotherapy group. At a minimum follow-up time (ie, time from random assignment of the last patient to data cutoff) of 17·6 months, overall survival was significantly improved in the nivolumab group compared with the chemotherapy group (median 10·9 months, 95% CI 9·2–13·3 <I>vs</I> 8·4 months, 7·2–9·9; hazard ratio for death 0·77, 95% CI 0·62–0·96; p=0·019). 38 (18%) of 209 patients in the nivolumab group had grade 3 or 4 treatment-related adverse events compared with 131 (63%) of 208 patients in the chemotherapy group. The most frequent grade 3 or 4 treatment-related adverse events were anaemia (four [2%]) in the nivolumab group and decreased neutrophil count (59 [28%]) in the chemotherapy group. Five deaths were deemed treatment-related: two in the nivolumab group (one each of interstitial lung disease and pneumonitis) and three in the chemotherapy group (one each of pneumonia, spinal cord abscess, and interstitial lung disease).</P> <P><B>Interpretation</B></P> <P>Nivolumab was associated with a significant improvement in overall survivaland a favourable safety profile compared with chemotherapy in previously treated patients with advanced oesophageal squamous cell carcinoma, and might represent a new standard second-line treatment option for these patients.

      • Physcial and Fiber Properties of TMP and CTMP from Kenaf Cultivated at Reclaimed Land of Korea

        SEUNG-LAK YOON,YASUO KOJIMA,DONG-HA CHO,NAM-HUM KIM,MIN-JOONG KIM,MYOUNG-KU LEE 한국펄프·종이공학회 2006 한국펄프종이학회 기타 간행물 Vol.- No.-

        Fiber characteristics and fiber distribution of thermomechanical pulp(TMP), bisulfite chemithermomechanical pulp(bisulfite CTMP), neutral sulfite chemithermomechanical pulp(neutral sulfite CTMP) from kenaf(Hibiscus cannabinus L., Malvaceae) cultivar Tainug-2 cultivated in the reclaimed land of Korea were examined to use effectively nonwood fibers as an alternative raw material sources for papermaking. Yields of TMP and CTMP from kenaf were lower than those of TMP from hardwoods and CTMP from softwoods and hardwoods. Bark fibers of kenaf cultivar Tainung-2 ranged 2.04 to 2.30 ㎜ long and 18.7∼19.7㎛ width. Core fibers averaged 0.63 to 0.80 ㎜ long and 29.5∼31.4㎛ wide. Coarseness of bark fiber was higher than that of core fiber, and fiber from TMP were higher than those from both bisulfite CTMP and neutral sulfite CTMP. Curl indexes of bark fibers were higher than those of core fibers. However curl indexes were not significantly affected by the pulping conditions. Short fiber distributions were higher in core fibers from TMP and CTMP and long fiber distributions were higher in bark fibers. There was no significant difference in fiber distribution of whole and core fibers obtained from TMP and CTMP. Fibers from neutral sulfite CTMP, however, exhibited a little higher long fiber distribution. Distinct difference in anatomical characteristics was found between core and bast fibers of kenaf plant. Parenchyma cell, pith parenchyma cell and vessel were observed in core fibers and bast fiber in bast sections.

      • SCOPUSKCI등재

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼